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Supplementary Figure 1: Circulating proteins reduced at 36 weeks’ gestation among women 
who will birth a small-for-gestational-age (SGA, birthweight <10th centile) infant. These are four 
proteins identified from screening 22 new circulating proteins in a case control cohort. SPINT1 (a,b; 
n= 210 controls, n=104 SGA, p=8.37x10-13), Syndecan-1 (c,d; n=99 controls, n=84 SGA, p=5.13x10-
8) and GDF-15 (e,f, n=99 controls, n=85 SGA, p=4.15x10-4) were significantly reduced in the plasma 
of women destined to deliver an SGA infant. DAPK1 (g,h; n=98 controls, n=84 SGA p=4.60x10-2) 
was significant increased in the SGA cohort. 105 cases of SGA and 210 matched controls. Individual 
symbols represent an individual patient. AUC – Area under the ROC curve, with 95% confidence 
intervals given in brackets. Data in panels a, c, e, g mean± s.e.m *p<0.05, ***p<0.001, ****p<0.0001 
using two-tailed Mann-Whitney U tests. Source data included as a source data file. 
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Supplementary Figure 2: Circulating analytes screened at 36 weeks that were detected in 
plasma but not changed among women destined to deliver a small-for-gestational-age (SGA) 
infant.  
These are 13 of 22 proteins screened in maternal plasma in a case control cohort at 36 weeks’ 
gestation. There were 105 cases of SGA (birthweight <10th centile) and 210 matched controls. 
Graphed here are proteins we screened that were detectable in the maternal plasma, but were not 
different in the two groups: COBLL1 (a), CRH (b), CSH1 (c), ENDOU (d), MAO (e), MICALL1 (f), 
PAPPA (g), S100P (h), SERPINB2 (i), FIBULIN-1 (j), hCG (k), SIGLEC 6 (l) and TFPI (m). 
Individual symbols represent individual patient analyte levels. The full names of the proteins are 





Supplementary Figure 3:  Validation of markers in Cohort 1 and 2.  
After identifying circulating Syndecan-1 and GDF-15 were significantly altered in the case control 
cohort at 36 weeks’ gestation we assayed both proteins in cohort 1 and 2.  We confirmed that maternal 
plasma concentrations of syndecan-1 (Cohort 1: a,b, p=1.22x10-5. Cohort 2 e,f, p=2.43x10-4) and 
GDF-15 (Cohort 1: c,d, p=1.55x10-4. Cohort 2: g,h p=1.68x10-2) were significantly reduced among 
women destined to deliver a small-for-gestational-age (SGA, birthweight <10th centile) infant.  In 
cohort 2 there was no significant change in sFlt-1 concentrations in the SGA group (i,j). a,b; n=894 
controls, n=106 SGA. c,d; n=895 controls, n=106 SGA. e,f,i,j; n=897 controls, n=105 SGA. g,h; 
n=893 controls, n=105 SGA.  Individual symbols represent an individual patient. AUC – Area under 
the ROC curve, with 95% confidence intervals given in brackets. Data in panels a, c, e, g, i mean± 
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s.e.m *p<0.05, ***p<0.001, ****p<0.0001using two-tailed Mann-Whitney U tests. Source data 





















































Supplementary Figure 4: SPINT1 levels are not associated with umbilical artery resistance, 
infant body fat percentage, or fat mass.  
A subgroup from the FLAG cohort had antenatal ultrasound measurements, and/or infant body 
composition assessed after birth using the PEAPOD air displacement plethysmography device. There 
was no relationship between circulating SPINT1 concentrations at 36 weeks and umbilical artery 
pulsatility index (a), neonatal body fat percentage (b) or neonatal fat mass (c).   We also examined 
whether SPINT1 concentrations were similar in plasma and serum (d). We measured SPINT1 in 
women who delivered a <10th centile baby at <34wks relative to levels in healthy controls – where 
each woman, we obtained both a plasma and serum sample at the same blood draw. While SPINT1 
was significantly reduced in the serum of women with SGA, the degree of change was far less than 
that observed in plasma. Individual symbols represent an individual patient. Panel a; n=327, b,c; 
n=281, d, data expressed as mean± s.e.m ****p<0.0001, *p<0.05 using two tailed Mann-Whitney U 















Supplementary Figure 5: Comparing the association between circulating SPINT1 and PlGF at 
36 weeks with clinical with markers of placental insufficiency.  
These were a subset of participants from the FLAG cohort. Compared to PIGF, circulating SPINT1 
concentrations appeared to have a stronger association with birth weight centile (a vs f), placental 
weight (b vs g), neonatal lean mass (c vs h) and uterine artery resistance (d vs i). Neither were 
significantly correlated with umbilical artery resistance (e and j). Each datapoint represents an 
individual patient. a; n=999, f; n=1002, b,g; n=96, c,h; n=136, d, e, i, j; n=63.   Source data included 







Supplementary Figure 6: Murine fetal, but not placental weights are reduced by maternal 
exposure to hypoxia.  
Following exposure to maternal hypoxia, fetal weight (a; n=9 normoxic, n=9 hypoxic from separate 
litters. c; n=13 normoxic, n=11 hypoxic from separate litters) but not placental weight (b; n=9 
normoxic, n=9 hypoxic from separate litters. d; n=13 normoxic, n=11 hypoxic from separate litters) 
was significantly reduced. Fetal and placental weights shown in a,b relate to the placentas where 
SPINT1 mRNA expression was measured (Figure 4e, main manuscript), whilst fetal and placental 
weights shown in c,d relate to the placentas where SPINT1 protein expression was assessed (Figure 
4f, main manuscript). Each individual symbol represents an individual fetus or placenta. Data 
expressed as mean± s.e.m ****p<0.0001 using two-tailed Mann-Whitney U tests. Source data 

























Age 32.3 (4.3) 32.6 (4.3) 0.46 
Booking body mass index 23.8 [21.5 – 28.5] 24.1 [21.7 – 27.4] 0.64 

















19 (17.9%) 119 (13.2%) 0.18 
Preeclampsia 7 (6.6%) 32 (3.6%) 0.18 
Onset of labour 
- Spontaneous 
- Induced 











Mode of birth 
- Normal vaginal birth 
- Instrumental delivery 











Gestation at delivery 
(weeks+days) 
39+0 [38+0 – 40+0] 39+5 [38+6 – 40+3] <0.0001 
Birthweight (g) 2728 [2448 – 2955] 3510 [3250 – 3800] <0.0001 
Birthweight centile 5.4 [2.7 – 8.2] 50.7 [30.0 – 75.0] <0.0001 
 
Supplementary Table 1: Maternal characteristics and pregnancy outcomes for Cohort 1 
Data presented as mean (standard deviation) if normally distributed data, as median [25th – 75th 
percentile] if not normally distributed data, and as number (%) if categorical. Small-for-gestational-







Supplementary Table 2: Maternal characteristics and pregnancy outcomes for Cohort 2 
Data presented as mean (standard deviation) if normally distributed data, as median [25th – 75th 
percentile] if not normally distributed data, and as number (%) if categorical. Small-for-gestational-




















Age 33.2 (4.2) 32.3 (4.1) 0.04 
Booking body mass index 24.7 [22.1 – 28.7] 24.4 [22.0 – 27.7] 0.11 
Nulliparous 44 (41.9%) 399 (44.5%) 0.68 
Cigarette Smoking 
- Current  
- Ex-smoker 













9 (8.6%) 114 (12.7%) 0.27 
Preeclampsia 7 (6.7%) 39 (4.3%) 0.32 
Onset of labour 
- Spontaneous 
- Induced 












Mode of Birth 
- Normal vaginal birth 
- Instrumental delivery 











Gestation at delivery 
(weeks+days) 
39+1 (1+2) 39+3 (1+1) 0.02 
Birthweight (g) 2750 [2590 – 2930] 3450 [3190 – 3740] <0.0001 

























Supplementary Table 3: Circulating proteins measured and the Commercial ELISAs used.  
Commercially available ELISAs were sourced to measure proteins of interest.  
sFlt-1 = soluble FMS-like tyrosine kinase-1 
PlGF = Placental growth factor 
GDF-15 = Growth differentiation factor-15 
DAPK1 = Death associated protein kinase 
COBLL1 = Cordon-Bleu protein Like 1 
CRH1 = corticotropin releasing hormone1 
ENDOU = endonuclease, poly(U) specific 
MAO =  Monoamine oxidase A 
MICALL-1 = MICAL-like protein 1 
PAPP-A = pregnancy-associated plasma protein-A 




Dilution (36 wks) Detection Range 
(pg/ml or as 
indicated) 
SPINT1 Sigma <12% 1:6 819 - 200,000 
SYNDECAN-1 Thermo Fisher <12% 1:35 16 - 4000 
sFlt-1 Roche <5% neat 10-85000 
PlGF Roche <5% neat 3-10000 
GDF-15 Thermo Fisher <12% 1:2000 1.1 - 800 
DAPK1 MyBioSource <10% neat 31 - 2000 
COBLL1 MyBioSource <10% neat 5000 - 100,000 
CRH MyBioSource <12% 1:5 15.6 - 1000 
CSH1 LifeSpan 
BioSciences 
<12% 1:10 2500 – 160,000 
ENDOU EIAab Science <10.4% 1:5 15.6 - 1000 
MAO Cusabio <10% 1:2 0.9 - 60IU/ml 
MICALL1 MyBioSource <15% neat 3120 -100,000 
PAPP-A R & D Systems Not 
found 
1:12  781 -50,000 
S100P MyBioSource <10% 1:2 or neat 78 - 5000 
SERBINB2 MyBioSource <12% 1:50 15.6 - 1000 
FIBULIN-1 EIAab ≤9.4% 1:4 470  - 30,000 
hCG ALPCO 
Diagnostics 
≤6.9% 1:200 5 - 300mIU/ml 
SIGLEC-6 R & D Systems Not 
found 
1:8 156 – 10,000 
TFPI R & D Systems Not 
found 
1:350  15.6 - 1000 
GM2A MyBioSource <10% not detectable 15.6 - 1000 
KISS1 Aviva Systems ≤5.9% most samples not 
detectable 
156 – 10,000 
PVRL3 MyBioSource <12% most samples not 
detectable 
156 – 10,000 
PSG6 MyBioSource <10% not detectable 312 – 20,000 
PTPRF CUSABIO <10% not detectable 6.25 - 400 
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SerbinB2 = PAI2 = Plasminogen activator inhibitor-2 
hCG = human chorionic gonadotrophin  
SIGLEC6 = Sialic acid binding Ig like lectin-6 
TFPI = Tissue factor pathway inhibitor 
GM2A = GM2 ganglioside activator  
KISS1 = kisspeptin-1 
PVRL3 = poliovirus receptor-related 3 
PSG6 = pregnancy specific beta-1-glycoprotein 6 








































Supplementary Table 4: Diagnostic performance of circulating plasma placental growth factor 














































10.1% 14.3% 19.7% 15.7% 1.0% 
Negative 
Predictive Value 













Sensitivity 42.3% 32.7% 21.7% 32.5% 12.5% 
Specificity 90.0% 89.9% 89.5% 77.7% 89.9% 
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Model 






LR + LR - 
<10th centile birthweight: 
Spint1 alone 0.66 (0.61 – 0.72) 24.5 2.46 0.84 
Spint1 adjusted for clinical 
factors 
0.66 (0.61 – 0.72) 22.7 2.26 0.86 
Clinical factors only 0.57 (0.51 – 0.63) 14.4 1.44 0.95 
<5th centile birthweight: 
Spint1 alone 0.71 (0.62 – 0.79) 36.7 3.71 0.70 
Spint1 adjusted for clinical 
factors 
0.70 (0.62 – 0.79) 37.2 3.74 0.70 
Clinical factors only 0.64 (0.55 – 0.72) 23.3 2.33 0.85 
<3th centile birthweight: 
Spint1 alone 0.75 (0.64 – 0.85) 42.3 4.23 0.64 
Spint1 adjusted for clinical 
factors 
0.76 (0.67 – 0.85) 41.7 4.18 0.65 
Clinical factors only 0.69 (0.59 – 0.78) 25.0 2.51 0.83 
 
Supplementary Table 5: Diagnostic performance of circulating SPINT1 at 36 weeks’ gestation to 
predict <10th, 5th and <3rd centile birthweights with adjustments for maternal clinical factors. Clinical 
factors adjusted for were age, smoking, parity and Body mass Index. Analysis was performed using 
logistic regression analysis. Analysis was done on cohort 2. Total numbers where all clinical variables 
were available for analyses were n = 967.  Numbers vary to those presented in table 1 (n=998) because 
of missing maternal characteristics for some patients. ROC – Receiver Operated Curve. CI – 























Supplementary Table 6: Diagnostic performance of circulating plasma SPINT1, GDF15, PlGF and 
Syndecan-1 concentrations at 36 weeks to predict infants born at <10th centile birthweight.  
1 lambda = 0.0018269, no variable dropped. ROC – Receiver Operated Curve. CI – Confidence 
























LR + LR - 
Logistic regression     
Spint1 + GDF15 + PIGF + 
Syndecan 
0.67 (0.62 – 0.73) 27.4 2.76 0.81 
Spint1 + GDF15   0.66 (0.61 – 0.72) 26.4 2.67 0.82 
Spint1 0.66 (0.61 – 0.72) 24.5 2.46 0.84 
GDF15 0.57 (0.52 – 0.63) 13.2 1.33 0.96 
PIGF 0.59 (0.53 – 0.65) 21.7 2.17 0.87 
Syndecan 0.61 (0.55 – 0.67) 17.9 1.80 0.91 
Lasso 1     
Spint1 + GDF15 + PIGF + 
Syndecan 























Supplementary Table 7: Diagnostic performance of circulating plasma SPINT1, GDF15, PlGF and 
Syndecan-1 concentrations at 36 weeks to predict infants born at <5th centile birthweight.  
1lambda = 0.0019988, no variable dropped. ROC – Receiver Operated Curve. CI – Confidence 

























LR + LR - 
Logistic regression     
Spint1 + GDF15 + PIGF + 
Syndecan 
0.72 (0.65 – 0.80) 34.7 3.49 0.73 
Spint1 + gdf15   0.71 (0.63– 0.79) 38.8 3.90 0.68 
Spint1 0.71 (0.62 – 0.79) 36.7 3.71 0.70 
GDF15 0.63 (0.54 – 0.71) 16.3 1.64 0.93 
PIGF 0.62 (0.53 – 0.71) 32.7 3.30 0.75 
Syndecan 0.63 (0.55 – 0.71) 16.3 1.65 0.93 
Lasso 1     
Spint1 + GDF15 + PIGF  + 
Syndecan 
0.72 (0.65 – 0.80) 34.7 3.49 0.73 
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LR + LR - 
Logistic regression     
Spint1 + GDF15 + PIGF  + 
Syndecan 
0.78 (0.68 – 0.88) 50.0 5.04 0.56 
Spint1 + GDF15   0.75 (0.64– 0.85) 42.3 4.27 0.64 
Spint1 0.75 (0.64 – 0.85) 42.3 4.24 0.64 
GDF15 0.62 (0.50 – 0.74) 15.4 1.55 0.94 
PIGF 0.69 (0.57 – 0.80) 42.3 4.28 0.64 
Syndecan 0.66 (0.56 – 0.77) 15.4 1.56 0.94 
Lasso 1     
Spint1 + GDF15 + PIGF  + 
Syndecan 
0.78 (0.68 – 0.88) 50.0 5.04 0.56 
 
Supplementary Table 8: Diagnostic performance of circulating plasma SPINT1, GDF15, PlGF and 
Syndecan-1 concentrations at 36 weeks to predict infants born at <3rd centile birthweight.  
1 lambda = 0.0008931, no variable dropped. ROC – Receiver Operated Curve. CI – Confidence 



























< 3rd centile 
Birthweight 
< 5th centile 
Birthweight 
< 10th centile 
Birthweight 
< 20th centile 
Birthweight 














(0.57 – 4.59) 
1.96 
(0.98 – 3.91) 
1.56 
(0.94 – 2.59) 
1.02 





Sensitivity 15.4% 18.4% 14.2% 10.6% 12.5% 
 
Specificity 90.0% 90.1% 90.0% 89.8% 89.9% 
 
 
Supplementary Table 9: Diagnostic performance of the sFlt/PIGF ratio in cohort 2.  



































Age 34.2 (5.6) 34.5 (4.9) 0.65 34.5 (5.4) 





- Multiparous (no prior 
history)§ 












Cigarette Smoking (current) 3/71 (4.2%) 5/189 (2.7%) 0.51 25/458 (5.4%) 
Hypertension 
- Chronic hypertension 













- Type 1 
- Type 2 
- Gestational DM 



















- <34 weeks 
- <37 weeks (inclusive <34) 
















- <10th centile 














Onset of labour 
- Spontaneous 
- Induced 
- No labour 


















Mode of birth 
- Normal vaginal birth 
- Instrumental delivery 
















- <37 weeks 













Gestation at birth (weeks+days) 37+3 [36+0 – 38+3] 38+3 [37+5 – 39+1] <0.001 38 [36+5-38+6] 
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Supplementary Table 10: Maternal characteristics and pregnancy outcomes for the Manchester 
Antenatal Vascular Service (MAViS) case-cohort study (n=291) included in this study. The last 
column shows the clinical characteristics of the entire MAViS cohort from which these samples were 
(n=518). 
§ Prior history of pre-eclampsia/placental disease (small for gestational age, pre-eclampsia, abruption, 
stillbirth with evidence of placental insufficiency) 


























Birthweight (g) 2551 [2100 – 2680] 3280 [2990 – 3530] <0.001 
2980 [2552-
3355] 





Supplementary Table 11: Clinical characteristics of a preterm fetal growth restriction cohort. These 
were cases where placental samples were collected from women delivered <34 weeks gestation with 
preterm fetal growth restriction (birthweight <10th centile), and preterm controls (birthweight >10th 
centile). 
BMI = body mass index, SBP = systolic blood pressure and DBP = diastolic blood pressure. BMI 
data missing for 5/23 preterm controls. SBP at booking data missing for 11/23 preterm controls and 
3/13 IUGR cases. 1/23 control and 1/13 FGR did not provide a read in initial western blot batch run 
and therefore are missing in Figure 4b. Presented as median [25th – 75th percentile], median 
(minimum, maximum) or number (%). Two tailed Mann-Whitney U tests used to compare continuous 



















Preterm controls born with a 
birthweight >10th centile 
(n=23) 
Preterm fetal growth 
restriction  
(n=13) 
Maternal Age (yrs)  32.1 [26.0-36.4] 29.9 [23.7-33.4] 
Gestation at 
Delivery(weeks) 30.0 [28.7-31.9] 31.4 [30.4-32.3] 
Body mass index  
(kg/m2) 27.3 [24.2-29.8] 23.0 [19.0-29.0] 
Parity no. (%) * 
   0 
   1 









SBP at Delivery (mmHg)  120 [113-130] 120 [117-130] 
DBP at Delivery (mmHg) 70 [70-80] 80 [70-83] 
Birthweight (g) * 1540 [1226-1823] 999 [870-1126] 
Male Number (%)  11 (48) 8 (62) 
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Supplementary Table 12: Clinical characteristics of cases where plasma samples were collected 
from women who eventually delivered <34 weeks’ gestation with preterm fetal growth restriction 
(birthweight <10th centile), and preterm controls (birthweight >10th centile). 
BMI = body mass index, SBP = systolic blood pressure and DBP = diastolic blood pressure. Presented 
as median [25th – 75th percentile], median (minimum, maximum) or number (%). Two-tailed Mann-



















Preterm controls born with a 
birthweight >10th centile 
 (n=15) 
Preterm fetal growth 
restriction 
 (n=9) 
Maternal Age (years)  32.0 [29.6 – 33.7] 33.5 [31.3 – 38.4] 
Gestation at Delivery*** 
(weeks) 39.6 [38.6 – 40.1] 28.6 [27.9 – 29.7] 
Gestation at Blood collection 
(weeks)  29.7 [26.9 – 30.7] 28.6 [27.4 – 29.1] 
BMI (kg/m2) 25.5 [23.5 – 28.0] 32.0 [27.1 – 34.4] 
Parity* no. (%)  
   0 
   1 









SBP at Delivery* (mmHg) 125 [120 – 128] 170 [155 – 175] 
DBP at Delivery* (mmHg) 79 [72 – 80] 95 [90-100] 
Birth weight (g) *** 3510 [3220 – 3805] 653 [623 – 859] 
Male Number (%) 5 (33) 3 (33) 
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Supplementary Methods 
Discovering circulating biomarkers of placental insufficiency 
To identify new biomarkers of placental insufficiency we performed the Fetal Longitudinal 
Assessment of Growth (FLAG) study. This included prospective collection of blood samples from 
pregnant women at 28 (27+0 – 29+0) and 36 (35+0 – 37+0 days) weeks’ gestation from 2015 participants. 
The FLAG study was undertaken at Mercy Hospital for Women, a tertiary referral hospital in 
Melbourne Australia. This study was approved by the Mercy Health Research Ethics Committee 
(Ethics Approval Number R14/12) and written informed consent was obtained from all participants. 
Identification of pregnancies that ended in the birth of a neonate that was small for gestational age 
(birthweight centile <10th) was pre-specified as the primary outcome in the study protocol.  
We also recruited a sub-cohort consisting of 347 nulliparous participants chosen from those enrolled 
in the FLAG study to undergo more intensive studies. For this sub-cohort, we performed ultrasound 
assessments at 28 and 36 weeks’ gestation, where several parameters were measured including 
Doppler assessment of blood flow resistance in the uterine, umbilical and the fetal middle cerebral 
arteries. Post birth, where possible, we measured neonatal body composition (lean body mass and fat 
mass) within 4 days of birth by performing air displacement plethysmography studies using a 
PEAPOD device (COSMED, Concord, CA, USA). Further methods for recruitment for the FLAG 
study are described below.  
To identify new biomarkers of placental insufficiency near term gestation we focused on the 36 week 
samples, where 1996 plasma samples were available. We divided the cohort approximately in half to 
discover, and then subsequently validate markers. Samples from the first 997 consecutively recruited 
participants constituted Cohort 1 and those from the second 998 consecutively recruited participants 
constituted Cohort 2. 
We initially screened 22 circulating proteins in a 1:2 nested case (105 neonates born small-for-
gestational-age, SGA, birthweight <10th centile) control (210 neonates born with a birthweight ≥10th 
centile) set selected from Cohort 1. The controls were group-matched to cases for maternal age, 
booking body mass index, smoking status, gestational diabetes mellitus, and parity. 
We selected proteins that are highly expressed in placenta relative to other tissues by referencing two 
bioinformatic databases. We selected proteins that were both 1) highly expressed at the mRNA level 
in placenta relative to all other human tissues using BioGPS (Biogps.org); and 2) abundantly 
expressed in its protein form on the membrane surface of the placenta (using Protein Atlas 
[www.proteinatlas.org]). The function of many of these proteins remain poorly understood. However, 
we postulated that because these are highly expressed in the placenta, most will play important 
biological roles and the expression of some may be perturbed in the presence of placental 
insufficiency.  
The proteins screened where circulating concentrations were different among cases of SGA compared 
to controls were re-assayed in a new batch assay run on all samples from Cohort 1. Those that 
remained significantly associated with SGA were then assayed in Cohort 2. We also measured 
placental growth factor (PIGF) and soluble fms-like tyrosine kinase-1 in Cohort 2. Further 
methodology detailing how the proteins were measured is included below. 
 
Developing diagnostic tests for placental insufficiency 
The intent of the FLAG study was to examine whether a combination of these markers was better at 
identifying fetal growth restriction, compared to one in isolation. We examined the diagnostic 
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performance of potential markers, either alone or in combination, to predict neonates born at 
birthweight centiles; <20th, <10th, <5th and <3rd; and those with birthweight <5th centile who required 
nursery admission (the latter is a small cohort likely to have suffered significant placental 
insufficiency).  
We generated potential diagnostic tests by examining whether we could combine the different 
proteins in results obtained in Cohort 2. We tried to develop modelling by setting the specificity at 
around 90%, which would equate to a 10% screen positive rate. We found SPINT1 performed the 
best and none of the other markers added to its performance. Therefore, we validated the diagnostic 
performance of SPINT1 in Cohort 1. To adjust for the fact that the research ELISA we used exhibited 
variability in reporting the absolute SPINT1 concentrations between the batches run for Cohorts 1 
and 2, we expressed SPINT1 results as multiples of the median (MoMs). 
We also developed (Cohort 2) a 4-tier model of risk for these different low birthweight ranges based 
on different SPINT1 MoM cut off levels. These cut-off levels were arbitrarily chosen when 
developing the test in Cohort 2. 
Further methods on describing the statistical analyses are detailed below. 
 
SPINT1 and other parameters of placental insufficiency 
We further investigated SPINT1 by correlating circulating levels with several other clinical indicators 
of placental insufficiency using data obtained from our sub-cohort study. We also measured 
circulating SPINT1 concentrations and placental expression in a separate cohort with fetal growth 
restriction delivered at <34 weeks gestation, where we performed further laboratory investigations in 
vitro, and in a mouse model of fetal growth restriction. Detailed methods on the laboratory studies 
are described below. 
 
Recruitment of samples for the FLAG cohort 
Women were screened for eligibility and were invited to participate at their oral glucose tolerance 
test, universally offered around 28 weeks’ gestation to test for gestational diabetes mellitus. Inclusion 
Criteria - English-speaking women aged over 18 years, with a singleton pregnancy and normal mid-
trimester fetal morphology examination were eligible to participate. Samples from women where a 
SGA fetus was suspected at the time of blood sampling were not excluded. Exclusion criteria – multi-
gestation pregnancies or pregnancies identified as having fetal anomalies.  
 
 
Maternal blood sample collection and preparation for the FLAG cohort 
Participants donated blood samples at between 27+0 to 29+0 weeks’ and/or 35+0 to 37+0 weeks’ 
gestation inclusive. Whole blood was collected in a 10ml ethylenediaminetetraacetic acid tube. 
Plasma was stored at -80°C until the time of sample analysis.  
 
 
Outcomes and definitions of cases for the FLAG cohort 
Maternal characteristics and pregnancy outcomes were obtained from review of each participant’s 






Birthweight centile calculations 
Infant birthweights were assigned a customised centile using the GROW software1 
(www.gestation.net), which generates a ‘term optimal weight’ based on an optimised fetal weight 
standard. We adjusted for the following non-pathological factors: maternal height, weight and parity; 
infant sex; and exact gestational age. Coefficients for the Australian dataset of GROW were informed 
by a local dataset; the multiple regression model has a constant to which weight is added or subtracted 
for each of the adjusted variables. SGA was defined as customised birthweight <10th centile. We 
compared the circulating protein levels among SGA cases, to those of the controls.  
We determined a priori plans to further investigate our most promising biomarkers for their 
association with several clinical parameters associated with placental insufficiency and fetal growth 
restriction by: (i) validating our findings in the entire first 1000 sample cohort; (ii) validating our 
findings in the second 1000 sample cohort; (iii) investigating the predictive potential of the biomarker 
in the 28 week blood samples; (iv) correlating candidate biomarkers with 36 week Doppler ultrasound 
parameters that are antenatal indicators of uteroplacental function; and (v) correlating candidate 
biomarkers with neonatal body composition measures – indicators of in utero nutrient supply.  
 
 
Doppler ultrasound parameters at 36 weeks 
Some nulliparous participants were also involved in the ultrasound-based arm of the FLAG study. 
For this, 347 women underwent a 36 (35+0-37+0) week ultrasound assessment where transabdominal 
colour and pulsed-wave Doppler were used to measure the mean maternal uterine artery pulsatility 
index (PI) and the umbilical artery PI. Measurements were taken during periods of fetal apnoea and 
inactivity with the angle of insonation close to zero.  The umbilical artery PI was measured in a free 
loop of umbilical cord away from cord insertion sites. For the maternal uterine artery the probe was 
placed in each of the iliac fossae, and the waveform recorded within 1cm of the uterine artery crossing 
the external iliac artery2. PI values were measured in triplicate and the mean calculated. Average 
uterine artery PI values were obtained for both the right and left vessels, and these averaged to provide 
the overall mean PI. For each of the PI values, the gestation-dependent centile (if normally 
distributed), or the multiples of the median (MoM) were determined. Treating clinicians were blinded 
to the uterine artery PI results. 
 
 
Inclusion and exclusion criteria for samples from the MAViS clinic 
 
To validate the observation that SPINT1 is associated with placental insufficiency we measured 
SPINT1 in a high-risk cohort from the United Kingdom – the Manchester Antenatal Vascular Service 
(MAViS clinic). Women gave written informed consent to donate samples for future research studies. 
The study was approved by the NRES Committee North West 11/NW/0426. 
 
The inclusion criteria for women in the MAViS study were: 1. chronic hypertension BP ≥140/90 at 
≤20 weeks; 2. chronic hypertension requiring antihypertensive treatment ≤ 20 weeks; 3. pre 
gestational diabetes with evidence of vascular complications (hypertension, nephropathy); 4. history 
of ischeamic heart disease and 5. previous early onset preeclampsia. 
 
Prespecified outcomes in the protocol for the MAViS biobank collection: primary outcome was the 
development of pregnancy complication requiring preterm birth (<37 weeks), secondary outcomes 
were the development of preeclampsia, birth of a small for gestational age neonate and early preterm 
birth (<34 weeks’ gestation). 
 
For our validation study cases and controls were selected from the MAViS biobank to specifically 
address whether SPINT1 was differentially expressed in pregnancies destined to deliver a neonate 
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<10th centile birthweight (see supplementary table 10). Hence, for the purposes of our present study, 
the delivery of a small for gestational age was our primary prespecified outcome.  
 
 
Recruitment and collection of samples from women with preterm fetal growth restriction  
Blood samples or placental samples were obtained from women with a diagnosis of preterm fetal 
growth restriction and were delivered at <34 weeks’ gestation, or gestation matched controls. Sample 
collection as part of the Mercy Tissue Bank was approved by the Mercy Health Research Ethics 
Committee (Ethics Approval Number R11/34) and written informed consent was obtained from all 
participants. Use of samples for this study was approved by the Mercy Health Research Ethics 
Committee (Ethics approval number R18/55). In this cohort fetal growth restriction <34 weeks’ 
gestation was pre-specified as the primary outcome.  
For the fetal growth restriction cohort, women were invited to participate when it was diagnosed on 
ultrasound. We also only included their samples if they were delivered <34 weeks’ gestation and 
growth restriction was confirmed following birth (by the fact that the neonatal weight was <10th 
centile).  
Controls were women who consented to blood collection at matched gestations but went on to deliver 
a normal sized infant (>10th centile) at term gestation.  
For the control group for the preterm placental samples we obtained placentas from women who were 
delivered for reasons other than fetal growth restriction or hypertensive diseases (the mother remained 
normotensive), such as vasa praevia, maternal medical conditions, spontaneous preterm labour or 
antepartum haemorrhage.  
For the placental studies all women were delivered by caesarean section for both the fetal growth 
restriction and control cohorts.   
Whole blood was collected in a 10ml ethylenediaminetetraacetic acid tube. Plasma was stored at -
80°C until the time of sample analysis.  Placental tissue was obtained immediately following delivery. 
Maternal and fetal surfaces were removed, and a sample was then washed briefly in sterile phosphate-
buffered saline (PBS). Samples for RNA or protein extraction were fixed in RNALater for 48 hours 
and then stored at -80°C.  
 
 
Mouse model of maternal hypoxia 
To assess the effect of maternal hypoxia on SPINT1, placentas were obtained from mothers exposed 
to hypoxia (10% inspired O2) or normoxia (21% inspired O2) from gestational day 14.5-19.5 as 
previously described5.  Briefly, virgin C57BL/6 J female mice, aged 6–8 weeks, were housed in 
groups of two to five per cage under a 12:12 h light:dark cycle at 22°C and were mated overnight 
with C57BL/6 J males. The presence of a copulatory plug was designated as day (D)1 of pregnancy 
(term ∼D20.5). All animals had ad libitum access to water and food [RM3, energy from fat 11%, 
protein 26%, carbohydrate 62% (simple sugar 7%), 15.3 MJ kg−1, diet code 801066; Special Diet 
Services, Witham, Essex, UK]. Mated females were weighed daily and the daily consumption of food 
and water was measured per cage to calculate intake per mouse per day. Pregnant mice were exposed 
to chronic, normobaric hypoxia for 5 day periods by placing their cages into an isolated PVC chamber 
(PFI Plastics Ltd, Milton Keynes, UK) in which the oxygen content was reduced to 10% by displacing 
oxygen with nitrogen using a nitrogen generator (N2MID60; Domnick Hunter Ltd, Warwick, UK).  
Control mice were maintained at room oxygen (21%).  All procedures described were approved by 
the Ethical Review Committee of the University of Cambridge (Cambridge, UK) and were carried 
out in accordance with UK Animals (Scientific Procedures) Act 1986 as previously reported 5.  
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On day 19 of gestation, dams were anesthetised before death (by cervical dislocation) with an 
intraperitoneal injection of fentanyl-fluanisone and midazolam in sterile water (1:1L2, 10 ug/mL; 
Janssen animal health). The uterus was removed, and all placentas were dissected free of fetus and 
membranes, weighed and immediately snap frozen whole in liquid nitrogen and stored at -80C for 
molecular analyses. For RNA and protein studies, 1 placenta per litter was included.  
Proteins were extracted from the second lightest placenta per litter (where possible) in lysis buffer 
containing 20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton X-100, 
2.5 mM sodium pyrophosphate, 1 mM b-glycerolphosphate, 1 mM Na3VO4, and complete mini 
proteases inhibitor cocktail (Roche Diagnostics, East Sussex, UK). Lysates protein concentration was 
determined using a Bicinchoninic acid assay (Sigma-Aldrich).  
RNA was extracted from the smallest placenta per litter (where possible) using the RNeasy Plus Mini 
Kit (Qiagen, Machester, UK) and the quantity of RNA determined using a NanoDrop 
spectrophotometer (NanoDrop Technologies, Inc.). From each sample, 2.5ug of total RNA was 
reverse transcribed to cDNA using High Capacity cDNA Reverse Transcription Kit with random 
primers (Applied Biosystems, Paisley,UK).  
 
 
ELISAs to measure circulating levels of proteins  
Commercially available protein-specific ELISAs were obtained and used to measure the 
concentration of each protein of interest in pg/ml (see table S3). Maternal plasma levels of sFlt-1 and 
PlGF were each measured with a commercial electrochemiluminescence immunoassay platform 




RT-PCR on human and mouse placenta 
To measure SPINT1 mRNA expression in human and mouse placenta, mRNA was extracted from 
20-30 mg of RNA later preserved frozen human placental samples by homogenization or from 
cytotrophoblast using an RNeasy mini-kit (Qiagen). 1μg of RNA was converted to cDNA using 
Applied Biosystems high capacity cDNA Reverse Transcriptase Kit (Life Technologies, Carlsbad, 
CA, USA). Taqman expression assays for human SPINT1, Murine Spint1, TOP1, CYC1, Ubc, Polr2A 
were used. For comparisons between human placental samples, data was normalised to the geometric 
mean of two housekeepers; TOP1 and CYC1. For mouse studies data was normalised to the geometric 
mean of Ubc and Polr2A.   RT-PCR was performed on the CFX 384 (Biorad, Hercules, CA, USA) 
using FAM-labeled Taqman universal PCR mastermix (Life Technologies) with the following run 
conditions: 50 oC for 2 minutes; 95 oC for 10 minutes, 95 oC for 15 seconds, 60 oC for 1 minute (40 
cycles).   
 
Taqman gene expression assays used were as follows: 
Taqman Gene Expression Assay, Hs00173678_m1 SPINT1 
Taqman Gene Expression Assay, Hs00243257_m1 TOP1 
Taqman Gene Expression Assay, Hs00357717_m1 CYC1 
Taqman Gene Expression Assay, Mm00444186_m1 Spint1 (mouse) 
Taqman Gene Expression Assay, Mm00839502_m1, Polr2a  







Western Blot on human and mouse placenta  
To examine SPINT1 protein expression, western blot analysis was undertaken on human and mouse 
placenta.  20μg of placental lysates (n=23 preterm and n=13 FGR) or 15 μg of trophoblast (n=11 
separate isolations) were separated on 10% SDS-polyacrylamide gels with wet transfer to PVDF 
membranes (Millipore, Billerica, MA). Membranes were blotted overnight with an antibody targeting 
SPINT1 (Rabbit anti-human SPINT1, Sigma, 1:250), an anti-GAPDH antibody for human placental  
samples (1:5000, Cell Signaling Technology, Danvers, MA, USA) or an anti-b-actin antibody for 
trophoblast samples (1:10,000, Sigma) and visualized using the Amersham ECLTM Prime Western 
blotting detection reagent (VWR International) and ChemiDoc XRS (BioRad, Hercules, CA, USA). 
Relative densitometry was determined in all samples using Image Lab (BioRad). 
For murine placental western blots, 20μg of placental lysates were separated on a 12% SDS-
polyacrylamide gel with wet transfer to PVDF membranes (Millipore, Billerica, MA). Membranes 
were blotted overnight with an antibody targeting murine SPINT1 (R&D systems, 1:2000 dilution) 
and b-actin followed by an anti-mouse HRP.  Protein bands were visulaised using the Amersham 
ECLTM Prime Western blotting detection reagent (VWR International) and ChemiDoc XRS 





Data summarized as mean (SD), median [25th – 75th percentile], median (minimum, maximum) and 
number (%) according to distribution. Hypothesis testing between SGA status used Mann-Whitney 
rank sum test for continuous and Fisher’s exact test for categorical data. Predictive performance, 
presented as point estimate and Wilson based 95% confidence intervals, was assessed using area 
under receiver operating characteristic curve (AUC area), sensitivity at 90% specificity and positive 
(PPV) and negative (NPV) at the known prevalence of SGA in this dataset. Multivariate logistic 
modelling was performed for all combinations of SPINT1, GDF15, DAPK1 and syndecan-1, 
predictive probability was calculated, and discrimination assessed using area under ROC curves and 
sensitivity at 90% specificity.  
LASSO penalized regression was also performed in analyses adjusting for maternal age, smoking 
status, parity and BMI. Comparison of area under ROC curves used the DeLong test statistic. For 
functional data a minimum of technical triplicates were performed for each biological replicate, with 
a minimum of three biological replicates (each from different patients) performed for each in-vitro 
study. When two groups were analysed a t-test (parametric) or a Mann-Whitney test (non-parametric) 
was used. For hypoxia data, a Wilcoxon matched pairs-ranks test was used. Significance level was 
set at 0.05 and no adjustment was made for multiple comparisons. Statistical software used was Stata 
v15 (StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC) 
and diagt program (Summary statistics for diagnostic tests. P. T. Seed and A. Tobias. Reprinted in 
Stata Technical Bulletin Reprints, vol. 10, pp. 90–93., from http://fmwww.bc.edu/RePEc/bocode/d 
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